LY-CoV555 and LY-CoV016 are two SARS-CoV-2 neutralizing antibodies which bind complementary regions of the SARS-CoV-2 spike protein. Studies are investigating their use in monotherapy and in combination. Only interim results are available at this time.
|Early||(Preprint)||hosp., ↓84.5%, p=0.05||SARS-CoV-2 neutralizing antibody program update|
|Interim results from the BLAZE-1 outpatient RCT showing improvements in viral load, symptoms and hospitalization. Combination therapy significantly reduced viral load at day 11 (p=0.011). A greater effect is seen at day 7 (p<0.001). The ..|